HRP20171301T1 - Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 - Google Patents
Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 Download PDFInfo
- Publication number
- HRP20171301T1 HRP20171301T1 HRP20171301TT HRP20171301T HRP20171301T1 HR P20171301 T1 HRP20171301 T1 HR P20171301T1 HR P20171301T T HRP20171301T T HR P20171301TT HR P20171301 T HRP20171301 T HR P20171301T HR P20171301 T1 HRP20171301 T1 HR P20171301T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- amino acid
- nos
- combination
- Prior art date
Links
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 title claims 3
- 229960000684 cytarabine Drugs 0.000 title claims 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 241001529936 Murinae Species 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Claims (19)
1. Farmaceutska kombinacija koja sadrži protutijelo koje specifično prepoznaje CD38 i barem citarabin, naznačena time da navedeno protutijelo je sposobno uništavati D38+ stanicu pomoću apoptoze, stanične citotoksičnosti ovisne o protutijelima (ADCC), i citotoksičnosti ovisne o komplementu (CDC).
2. Kombinacija prema zahtjevu 1, naznačena time da navedeno protutijelo je humanizirano protutijelo.
3. Kombinacija prema zahtjevu 1 ili zahtjevu 2, naznačena time da je navedeno protutijelo humanizirano protutijelo proizvedeno pomoću resurfacinga.
4. Kombinacija prema zahtjevu 2 ili zahtjevu 3 naznačena time da navedeno protutijelo sadrži jednu ili više regija koje određuju komplementarnost koje imaju sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 i 36.
5. Kombinacija prema zahtjevu 2 ili zahtjevu 3, naznačena time da je navedeno protutijelo humanizirana verzija mišjeg protutijela 38SB19, pri čemu teški lanac navedenog mišjeg protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu laki lanac navedenog protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
6. Kombinacija prema zahtjevu 5, naznačena time da je navedeno protutijelo 38SB19 protutijelo proizvedeno pomoću hibridoma pohranjenog u American Type Culture Collection pod pristupnim brojem PTA-7670.
7. Kombinacija prema bilo kojem od zahtjeva 1 do 4 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline prikazanu sa SEQ ID NO: 66 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu navedeni laki lanac sadrži sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 62 i 64, i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
8. Kombinacija prema bilo kojem od zahtjeva 1 do 4 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac ima sekvencu aminokiseline prikazanu sa SEQ ID NO: 72 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 25, 26, i 27, te pri čemu navedeni laki lanac ima sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 68 i 70 i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 28, 29, i 30.
9. Farmaceutska kombinacija prema bilo kojem od zahtjeva 1 do 8, naznačena time da navedena farmaceutska kombinacija je farmaceutski pripravak koji sadrži navedeno anti-CD38 protutijelo u kombinaciji s citarabinom.
10. Farmaceutska kombinacija prema zahtjevu 1 naznačena time da je za upotrebu za liječenje raka.
11. Kombinacija za upotrebu prema zahtjevu 10, naznačena time da navedeno protutijelo je humanizirano protutijelo.
12. Kombinacija za upotrebu prema zahtjevu 10 ili zahtjevu 11, naznačena time da navedeno protutijelo je humanizirano protutijelo proizvedeno pomoću resurfacinga.
13. Kombinacija za upotrebu prema zahtjevu 11 ili zahtjevu 12, naznačena time da navedeno protutijelo je humanizirana verzija mišjeg protutijela 38SB19, pri čemu teški lanac navedenog mišjeg protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu laki lanac navedenog protutijela 38SB19 sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
14. Kombinacija za upotrebu prema zahtjevu 13, naznačena time da navedeno 38SB19 protutijelo je protutijelo proizvedeno pomoću hibridoma pohranjenog u American Type Culture Collection pod pristupnim brojem PTA-7670.
15. Kombinacija za upotrebu prema zahtjevu 10 naznačena time da navedeno protutijelo sadrži jednu ili više regija koje određuju komplementarnost koje imaju sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 i 36.
16. Kombinacija za upotrebu prema zahtjevu 13 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline prikazanu sa SEQ ID NO: 66 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 13, 14, i 15, te pri čemu navedeni laki lanac sadrži sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 62 i 64 i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 16, 17, i 18.
17. Kombinacija za upotrebu prema zahtjevu 13 naznačena time da navedeno protutijelo sadrži barem jedan teški lanac i barem jedan laki lanac, pri čemu navedeni teški lanac sadrži sekvencu aminokiseline prikazanu sa SEQ ID NO: 72 i/ili navedeni teški lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 25, 26, i 27, te pri čemu navedeni laki lanac sadrži sekvencu aminokiseline odabranu iz skupine koju čine SEQ ID NOS: 68 i 70 i/ili navedeni laki lanac sadrži tri uzastopne regije koje određuju komplementarnost koje imaju sekvence aminokiselina prikazane sa SEQ ID NOS: 28, 29, i 30.
18. Kombinacija prema zahtjevu 9 ili za upotrebu prema zahtjevima 10-15, naznačena time da su sastojci navedene kombinacije za odvojenu primjenu.
19. Kombinacija prema zahtjevu 9 ili za upotrebu prema zahtjevima 10-15, naznačena time da su sastojci navedene kombinacije za istovremenu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291118A EP2191842A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| PCT/IB2009/055391 WO2010061359A1 (en) | 2008-11-28 | 2009-11-27 | Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine |
| EP09775304.0A EP2370096B1 (en) | 2008-11-28 | 2009-11-27 | Antitumor combinations containing cytarabine and antibodies recognizing specifically cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171301T1 true HRP20171301T1 (hr) | 2017-10-20 |
Family
ID=40627502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171301TT HRP20171301T1 (hr) | 2008-11-28 | 2017-08-30 | Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US20120093806A1 (hr) |
| EP (2) | EP2191842A1 (hr) |
| JP (2) | JP2012510463A (hr) |
| KR (1) | KR101715958B1 (hr) |
| CN (2) | CN107096022A (hr) |
| AR (1) | AR073425A1 (hr) |
| AU (1) | AU2009321251B2 (hr) |
| BR (1) | BRPI0921858B1 (hr) |
| CA (1) | CA2745005C (hr) |
| CL (1) | CL2011001232A1 (hr) |
| CO (1) | CO6440556A2 (hr) |
| CR (1) | CR20110282A (hr) |
| DK (1) | DK2370096T5 (hr) |
| EA (1) | EA027070B1 (hr) |
| EC (1) | ECSP11011071A (hr) |
| ES (1) | ES2638926T3 (hr) |
| HN (1) | HN2011001423A (hr) |
| HR (1) | HRP20171301T1 (hr) |
| HU (1) | HUE035910T2 (hr) |
| IL (2) | IL213118A (hr) |
| LT (1) | LT2370096T (hr) |
| MA (1) | MA32899B1 (hr) |
| MX (1) | MX344973B (hr) |
| NI (1) | NI201100107A (hr) |
| NZ (1) | NZ593085A (hr) |
| PA (1) | PA8849901A1 (hr) |
| PE (1) | PE20120205A1 (hr) |
| PL (1) | PL2370096T3 (hr) |
| PT (1) | PT2370096T (hr) |
| RS (1) | RS56248B1 (hr) |
| SG (1) | SG171821A1 (hr) |
| SI (1) | SI2370096T1 (hr) |
| TN (1) | TN2011000242A1 (hr) |
| TW (1) | TWI436770B (hr) |
| UA (1) | UA104160C2 (hr) |
| UY (1) | UY32266A (hr) |
| WO (1) | WO2010061359A1 (hr) |
| ZA (1) | ZA201104064B (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| RU2595839C2 (ru) | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2650618C2 (ru) | 2012-09-25 | 2018-04-16 | МорфоСис АГ | Комбинации и их применение |
| KR20210043006A (ko) * | 2013-03-13 | 2021-04-20 | 사노피 | 항-cd38 항체 및 카르필조밉을 포함하는 조성물 |
| SG10201803288RA (en) * | 2013-10-31 | 2018-05-30 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| MX2017014810A (es) | 2015-05-20 | 2018-05-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| IL256242B1 (en) | 2015-06-22 | 2024-05-01 | Janssen Biotech Inc | Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CA2998611A1 (en) * | 2015-09-14 | 2017-03-23 | Leukemia Therapeutics, LLC | Identification of novel diagnostics and therapeutics by modulating rhoh |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| ES2912729T3 (es) | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| EP3938394A1 (en) | 2019-03-15 | 2022-01-19 | MorphoSys AG | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| CA3160502A1 (en) | 2019-12-05 | 2021-06-10 | Thomas Ballet | Formulations of anti-cd38 antibodies for subcutaneous administration |
| KR20230142834A (ko) | 2021-01-14 | 2023-10-11 | 모르포시스 아게 | 항-cd38 항체 및 이의 용도 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| CN113278075B (zh) * | 2021-06-18 | 2021-12-14 | 芜湖森爱驰生物科技有限公司 | 一种炎症检测试剂盒 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2329940A1 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| ES2716874T3 (es) * | 2005-03-23 | 2019-06-17 | Genmab As | Anticuerpos contra cd38 para el tratamiento del mieloma múltiple |
| DK2081595T3 (da) * | 2006-09-26 | 2019-07-15 | Genmab As | Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US8551485B2 (en) * | 2008-01-23 | 2013-10-08 | Xencor, Inc. | Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
-
2008
- 2008-11-28 EP EP08291118A patent/EP2191842A1/en not_active Ceased
-
2009
- 2009-11-25 TW TW098140152A patent/TWI436770B/zh active
- 2009-11-25 AR ARP090104547A patent/AR073425A1/es not_active Application Discontinuation
- 2009-11-25 PA PA20098849901A patent/PA8849901A1/es unknown
- 2009-11-25 UY UY0001032266A patent/UY32266A/es not_active Application Discontinuation
- 2009-11-27 MX MX2011005666A patent/MX344973B/es active IP Right Grant
- 2009-11-27 AU AU2009321251A patent/AU2009321251B2/en active Active
- 2009-11-27 HU HUE09775304A patent/HUE035910T2/en unknown
- 2009-11-27 CA CA2745005A patent/CA2745005C/en not_active Expired - Fee Related
- 2009-11-27 DK DK09775304.0T patent/DK2370096T5/en active
- 2009-11-27 CN CN201710103901.7A patent/CN107096022A/zh active Pending
- 2009-11-27 BR BRPI0921858-0A patent/BRPI0921858B1/pt active IP Right Grant
- 2009-11-27 ES ES09775304.0T patent/ES2638926T3/es active Active
- 2009-11-27 NZ NZ593085A patent/NZ593085A/xx not_active IP Right Cessation
- 2009-11-27 PE PE2011001097A patent/PE20120205A1/es not_active Application Discontinuation
- 2009-11-27 UA UAA201108055A patent/UA104160C2/uk unknown
- 2009-11-27 LT LTEP09775304.0T patent/LT2370096T/lt unknown
- 2009-11-27 WO PCT/IB2009/055391 patent/WO2010061359A1/en active Application Filing
- 2009-11-27 KR KR1020117014748A patent/KR101715958B1/ko active IP Right Grant
- 2009-11-27 CN CN2009801481843A patent/CN102264386A/zh active Pending
- 2009-11-27 EA EA201100868A patent/EA027070B1/ru not_active IP Right Cessation
- 2009-11-27 SG SG2011037975A patent/SG171821A1/en unknown
- 2009-11-27 PL PL09775304T patent/PL2370096T3/pl unknown
- 2009-11-27 SI SI200931726T patent/SI2370096T1/sl unknown
- 2009-11-27 JP JP2011538094A patent/JP2012510463A/ja not_active Withdrawn
- 2009-11-27 PT PT97753040T patent/PT2370096T/pt unknown
- 2009-11-27 RS RS20170860A patent/RS56248B1/sr unknown
- 2009-11-27 EP EP09775304.0A patent/EP2370096B1/en active Active
- 2009-11-27 US US13/130,867 patent/US20120093806A1/en not_active Abandoned
-
2011
- 2011-05-17 TN TN2011000242A patent/TN2011000242A1/fr unknown
- 2011-05-23 EC EC2011011071A patent/ECSP11011071A/es unknown
- 2011-05-24 IL IL213118A patent/IL213118A/en active IP Right Grant
- 2011-05-24 IL IL213115A patent/IL213115A/en active IP Right Grant
- 2011-05-26 CR CR20110282A patent/CR20110282A/es unknown
- 2011-05-26 CL CL2011001232A patent/CL2011001232A1/es unknown
- 2011-05-27 HN HN2011001423A patent/HN2011001423A/es unknown
- 2011-05-27 CO CO11065641A patent/CO6440556A2/es unknown
- 2011-05-27 NI NI201100107A patent/NI201100107A/es unknown
- 2011-06-01 ZA ZA2011/04064A patent/ZA201104064B/en unknown
- 2011-06-13 MA MA33941A patent/MA32899B1/fr unknown
-
2015
- 2015-06-01 JP JP2015111127A patent/JP6072854B2/ja active Active
-
2017
- 2017-08-30 HR HRP20171301TT patent/HRP20171301T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171301T1 (hr) | Antitumorske kombinacije koje sadrže citarabin i protutijela koja specifično prepoznaju cd38 | |
| HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| UA114879C2 (uk) | Антитіло до cd38 для лікування раку | |
| HRP20211023T1 (hr) | Anti-her2 protutijelo i njegov konjugat | |
| RU2013141956A (ru) | Антитело против ксф-1r | |
| JP2012510461A5 (hr) | ||
| MX2009003838A (es) | Anticuerpos anti-cd20 y metodos de uso. | |
| AR074221A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamida | |
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| NZ612055A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| RS54452B1 (en) | INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ595464A (en) | Alpha-4-beta-7 heterodimer specific antagonist antibody | |
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| HRP20191590T1 (hr) | Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen | |
| FI3137504T3 (fi) | Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten | |
| MX2007007484A (es) | Anticuerpos dirigidos a angiopoyetina 2 y usos de los mismos. | |
| UY29573A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
| IL290591B1 (en) | Antibody drug preparations (ADC) that bind to 191P4D12 proteins | |
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan |